ABSTRACT mTOR inhibition can promote or inhibit immune responses in a context dependent manner, but whether this will represent a net benefit or be contraindicated in the context of immunooncology therapies is less understood. Here, we report that the mTORC1/2 dual kinase inhibitor vistusertib (AZD2014) potentiates anti-tumour immunity in combination with anti-CTLA-4 (aCTLA-4), aPD-1 or aPD-L1 immune checkpoint blockade. Combination of vistusertib and immune checkpoint blocking antibodies led to tumour growth inhibition and improved survival of MC-38 or CT-26 pre-clinical syngeneic tumour models, whereas monotherapies were less effective. Underlying these combinatorial effects, vistusertib/immune checkpoint combinations reduced the occurrence of exhausted phenotype tumour infiltrating lymphocytes (TILs), whilst increasing frequencies of activated Th1 polarized T-cells in tumours. Vistusertib alone was shown to promote a Th1 polarizing proinflammatory cytokine profile by innate primary immune cells. Moreover, vistusertib directly enhanced activation of effector T-cell and survival, an effect that was critically dependent on inhibitor dose. Therefore, these data highlight direct, tumour-relevant immune potentiating benefits of mTOR inhibition that complement immune checkpoint blockade. Together, these data provide a clear rationale to investigate such combinations in the clinic.
Introduction
Evasion from anti-tumour immunity is a hallmark feature of cancer. Whilst strategies employed by the tumour to avoid immune-mediated clearance are complex and multifaceted, some therapeutic approaches to promote anti-tumour immunity are emerging. Antibody-mediated blockade of immune-checkpoint receptors is now clinically approved across a range of indications, 1 however such treatments lack sustained efficacy in the majority of patients. 2 Thus, a deeper understanding of therapeutic interventions represents an area of unmet clinical need. Given that redundancy may exist between immunosuppressive mechanisms utilized by a tumour, there is great scope to improve clinical responses by combining existing immune-targeting and/or tumour targeting therapies in a rational manner.
The mechanistic target of rapamycin (mTOR) signalling pathway represents a key pathway in many human cancers. [3] [4] [5] Therapeutic mTOR inhibition has been well studied as a tumour targeting agent in the context of many tumour types, including ER C breast cancer in combination with endocrine therapy. 6 mTOR kinase functions in the context of multiprotein complexes termed mTORC1 and mTORC2, which under physiological conditions can be engaged by a variety metabolic, stress and immunological signals in immune cell populations. Inhibitors of mTOR signalling have been long believed to be profoundly immunosuppressive, and blockade of mTOR signalling with the allosteric mTORC1 inhibitor rapamycin inhibits effector T-cell expansion following mitogen treatment. 7 To this end, structurally related compounds (collectively termed rapalogues) have been used clinically to prevent graft rejection following transplantation. 8 However, an emerging body of literature suggests that in some immunological contexts, mTOR inhibition can also potentiate immune responses. 9, 10 Given the unusual nature of the suppressed immune-microenvironment within a tumour, and the pleiotropic impacts of mTOR inhibitors on distinct immune cell subsets, it remains unclear whether mTOR inhibition will suppress anti-tumour immunity, 11 or whether it will potentiate anti-tumour responses. 12, 13 Interpretation of these questions has been obscured by the use of mTORC1-targeting rapalogues, that deliver incomplete pathway inhibition, 14 or by non-clinical quality mTOR kinase inhibitor compounds which may possess off-target activity at therapeutically relevant doses. 15 To systematically address the immunological impact of acute mTOR inhibition in cancer, we investigated the impact of the clinical dual mTORC1/2 kinase inhibitor vistusertib (AZD2014) in the context of anti-tumour immunotherapy.
Results mTOR kinase inhibition with vistusertib potentiates the effects of immune checkpoint blockade in preclinical tumour models Vistusertib (AZD2014) is a potent, orally available, mTOR kinase inhibitor, with a reported IC 50 in sensitive tumour cell lines of between 100-200 nM, 6 and is under investigation as a tumour targeted agent against both solid and hematological malignancies. To investigate whether primary immune cells were sensitive to vistusertib treatment, we first asked whether vistusertib inhibited downstream mTOR pathway targets in primary CD8
C T-cells. Following in vitro activation, we observed dose-dependent inhibition of mTORC1 complex signaling (measured by phosphorylation of S6 on Ser240/244) with a similar potency to sensitive tumour cell lines (Fig. S1A) . 6 This contrasted treatment with rapamycin, which promoted an extremely potent inhibitory effect on pS6 (Ser240/244) at sub-pM concentrations (Fig. S1B) . Phosphorylation of the alternative mTORC1 target 4Ebp1 (Thr36/45) was previously shown to be less sensitive to rapamycin-mediated inhibition compared to pS6 (Ser240/244). 16 Comparably vistusertib was capable of inhibiting p4Ebp1 (Thr36/45) to a greater extent than rapamycin (Fig. S1C) . Vistusertib also inhibited mTORC2 signaling (measured by phosphorylation of Akt on Ser473) in primary na€ ıve T-cells, further differentiating vistusertib from rapamycin, which preferentially targeted mTORC1 (Fig. S1D-E) . We further confirmed mTORC2 target engagement in immunoinfiltrated CT-26 syngeneic tumours in vivo, finding robust inhibition of Akt Ser473 4h after dosing (Fig. S1F) . Therefore, vistusertib promoted acute mTOR pathway inhibition in primary native T-cells, and exhibited a differentiated pharmacology consistent with mTOR kinase inhibition.
Given the sensitivity of immune cells to vistusertib, we further investigated whether mTOR kinase inhibition influenced anti- tumour immunity in the context of immune-checkpoint blockade. We investigated the vistusertib/immune checkpoint combinations in mice bearing syngeneic MC-38 tumour. MC-38 is derived from a colorectal (CRC) tumour and has a predominant infiltration of myeloid cells in relation to T and NK cells. 17 MC-38 tumours were modestly sensitive to either checkpoint blockade (aPD-1, aCTLA-4 and aPD-L1) or mTORC1/2 inhibiton as a monotherapy. However significant anti-tumour effects were observed when combining vistusertib and checkpoint blockade (Fig. 1A) , along with improved survival compared to treatment with each single agent (Fig. 1B-D) . Taken together these data sugget that mTORC1/2 inhibitors have a positive anti-tumour effect in combination with immuno-checkpoint blockade.
To confirm the applicability of these observations to additonal tumour models, we further investigated the vistusertib/checkpoint blockade combination in a second model, CT-26. CT-26 tumour cells harbour an activating mutation in K-Ras, 18 which commonly confers resistance to PI3K/mTORC1/2 inhibition. 19, 20 We confirmed this prediction, observing that CT-26 tumours were insensitive to vistusertib when delivered with a regimen that promotes anti-tumour efficacy in sensitive tumour cell lines. 6 . Interestingly, vistusertib potentiated anti-tumour efficacy when co-administered as a combination therapy with aCTLA-4 immune-checkpoint blockade ( Fig. 2A-B) , although the CT-26 model did not respond to aPD-L1 (data not shown). Pharmacokinetic (PK) experiments demonstrated that the dosing regimen employed achieved exposures over the cellular IC 50 for »15-20 hours, and that PK properties were not impacted by either the presence of a CT-26 tumour, or the administration of aCTLA-4 blocking antibodies (Fig. S1E) . Therefore in two models that represent varied immunological landscapes, vistusertib showed combinatorial with immune checkpoint blockade to potentiate antitumour activity and survival. mTOR inhibition reverses the exhausted phenotype of tumour infiltrating CD8
C T-cells mTOR inhibition is associated with both suppression and potentiation of immunity, which depends on the immunological context. Given the enhanced anti-tumour effect observed when vistusertib was combined with immune checkpoint blockade, we hypothesized that in the context of cancer immunotherapy, vistusertib may potentiate anti-tumour immune cell functions. To investigate this concept, we measured pharmacodynamic (PD) changes in vistusertib treated CT-26 tumour bearing mice in the presence or absence of aCTLA-4 immunecheckpoint inhibition. aCTLA-4 administration conferred a trend of enhanced CD45 C hematopoietic cell recruitment to tumours, an effect that was significantly potentiated by vistusertib (Fig. 2C ). Vistusertib did not significantly impact NK cell frequencies under conditions tested (Fig. 2D) . Instead, we observed a reduction in the frequency of both Foxp3
C regulatory T-cells (Tregs), and CD8
C T-cells infiltrating the tumours in vistusertib/aCTLA-4 combination groups, as compared to aCTLA-4 treatment alone (Fig. 2E-F) . Thus, we found direct evidence that vistusertib therapy modulated the tumourimmune microenvironment and impacted both pro-tumourigenic and anti-tumourigenic immune populations.
To better understand how mTOR inhibition could impact the functional state of the tumour-immune infiltrate, we performed tSNE analysis on our high dimensional flow cytometry dataset generated from mice bearing CT-26 tumours. 21 Interestingly, we observed the monotherapeutic aCTLA-4 immune checkpoint administration resulted in clusters of PD-1 C T-cells (Fig. 3A) , supporting recent observations that immune checkpoint blocking antibodies preferentially expand exhausted phenotype T-cells in both mice and man. 22 However, T-cell populations appeared functionally less exhausted in vistusertib treated tumour bearing mice, exhibiting lower expression of the exhaustion marker PD-1 ( Fig. 3A-C ). In keeping with this observation, we also observed an increased proportion of cells expressing the high affinity IL-2 receptor CD25, which marks activated/effector cells and of the cytotoxic functional marker Granzyme B (GzmB) (Fig. 3D-E ). IFNg is a major cellular effector cytokine produced by cytotoxic and Th1 polarized T-cells, which serves to enhance antigen presentation of tumour and recruit cytotoxic immune cells. 23 Analysis of tumour aqueous extract revealed that vistusertib/aCTLA-4 treated mice maintained high levels of IFNg (Fig. 3F) . Similar results were also observed in MC-38 tumour bearing mice, where the vistusertib/aCTLA-4 combination enhanced the frequencies of CD8
C Tcells expressing the activation marker ICOS C (Fig. 3G ), which is a positive biomarker of aCTLA-4 therapeutic and clinical responses. 24 Moreover, vistusertib/aCTLA-4 combination significantly enhanced the proportion of IFNg expressing CD8 C T-cells (Fig. 3H) . Finally, combination of vistusertib and aCTLA-4 blockade was inactive in nude mice lacking mature T-cells (Fig. S2A-B) , supporting the improving T-cell activation profile as the main mode of action. When taken together, our data indicate the clinical mTOR kinase inhibitor vistusertib synergizes with aCTLA-4 immune checkpoint blockade by reducing the level of CD8 C T-cell exhaustion, and had a net effect to enhance anti-tumour effector responses.
Vistusertib enhances the proinflammatory cytokine profile of APCs
To understand the direct cellular targets that result in immunopotentiated phenotypes, we considered that mTOR signaling can restrain immunity in a variety of contexts. This is perhaps best characterized in innate immune cells, where pharmacological inhibition or genetic ablation of mTOR can promote proinflammatory cytokine production by antigen presenting cells (APCs). 10, [25] [26] [27] [28] [29] To investigate whether vistusertib promoted a proinflammatory/cytotoxic innate immune cytokine profile, bone-marrow derived DCs (BMDCs) were generated from WT bone marrow and activated in vitro, in the presence of vistusertib, or the mTORC1 inhibitor rapamycin. Both vistusertib and rapamycin reduced expression of the immunosuppressive cytokine IL-10, but the impacts were far more striking with vistusertib at doses >100nM (Fig. 4A) . In addition, production of the pro-inflammatory Th1 promoting cytokine IL-12 was enhanced Fig. 4B ), whereas other pro-inflammatory cytokines IL-6 and TNF were unaffected by mTOR inhibition (Fig. 4C) , Fig. S3A ), consistent with previous reports. 26, 28 The exquisite sensitivity of IL-10 production to mTOR signaling was confirmed over a wider dose range by Meso Scale Discovery (MSD), revealing the EC 50 of the IL-10 inhibitory effect conferred by vistusertib was between »30-100nM (Fig. S3B) . Finally, the impact of vistusertib on IL-10 and IL-12 was additionally observed to occur at the transcriptional level (Fig. 4D) . Together, these observations prompted us to investigate whether vistusertib influenced the cytokine milieu in CT-26 tumours. Here, we observed a significant decrease in IL-10 mRNA, in addition to a 1.5 fold increase in IL-12 mRNA. Examining individual mice revealed that vistusertib was able to positively skew the IL-12:IL-10 ratio in tumours (Fig. 4E) . We concluded that mTOR inhibition with vistusertib may contribute to enhanced pro-inflammatory modality of tumour resident antigen presenting cells, which is a likely contributor to its synergistic therapeutic benefit with immune checkpoint blockade.
Vistusertib enhances the survival of weakly activated effector CD8
C T-cells
Given evidence that vistusertib potentiated the T-cell response against tumours, we also investigated whether mTOR inhibition could directly modulate T-cell function. Intratumoural Tcells are likely to be sub-optimally activated and the impact of mTOR inhibition in such a context has not been reported. 30, 31 We therefore developed an in vitro assay to model a suboptimal stimulatory environment. Purified CD8 C na€ ıve T-cells were cultured at a 1:1 ratio with aCD3/aCD28 coated T-cell activation beads or aCD3 coated plates with soluble aCD28. Culture with activation beads resulted in a sub-optimal activation, as measured by the activation marker CD69, and could be further augmented upon addition of IL-2 (Fig. S4A) . Activated T-cells produce autocrine IL-2 to support their ongoing differentiation/survival, and IL-2 signalling promotes upregulation of the high affinity receptor CD25 as part of a feed-forward loop. 32, 33 In our culture system, IL-2 addition could also enhance CD25 expression on sub-optimally stimulated T-cells (Fig. S4B) , suggesting that autocrine IL-2 production was rate-limiting under these conditions. As expected, IL-2 did not impact the expression of CD5, a surface protein that is uniquely regulated by TCR signalling (Fig. S4C) . 34, 35 Finally, despite aCD3/aCD28 bead stimulation promoting a weaker T-cell activation, the differentiation marker CD44 was nevertheless upregulated, suggesting that differentiation from na€ ıve to T-effector cells was still preserved (Fig. S4D) .
Having established a weak T-cell activation assay, we asked whether mTOR inhibitors could potentiate or inhibit this process. Whilst high doses of vistusertib profoundly blocked Tcell proliferation, doses under 1mM preserved T-cell proliferative capacity. This dose response contrasted that of the well characterized mTORC1 inhibitor rapamycin, which partially inhibited T-cell proliferation at all doses investigated (Fig. 5A-B) . Indeed, these results were reminiscent of the subtly reduced T-cell accumulation observed in tumours in vivo (Fig. 2E) . However, we additionally observed that vistusertib enhanced survival of activated T-cells at intermediate doses (Fig. 5C) . Whilst a pro-survival phenotype following mTOR inhibition has been previously reported in memory precursor cells, 36 this represented an unexpected finding in freshly activated T-effector cells. To better understand the mechanism underlying vistusertib-dependent CD8 T-effector cell survival, we examined the expression of a panel of pro-and anti-apoptotic factors that have been previously associated with T-cell population dynamics in the thymus. 37 This analysis revealed a vistusertib-dependent upregulation of the pro-survival gene Bcl2 (Fig. 5D) , but not the related prosurvival gene Bcl2l1, which encodes Bclxl (Fig. S5) . To confirm the significance of this finding, we examined Bcl2 protein expression after 4d of culture. Rather than representing a global increase in Bcl2 expression, we found that vistusertib promoted accumulation of a CD25
C
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hi subpopulation of cells (Fig. 5E) . When taken together, we conclude that intermediate doses of vistusertib enhance the survival of weakly activated CD8
C T-effector cells. Given the in vivo pharmacokinetic exposure profile (Fig. S1G) , and observed dose-dependent impacts of vistusertib on T-cell proliferation and survival, we reasoned that the preferential survival of effector cells could account for a global reduction of T-cell frequencies, but relative enrichment for effector T-cells in tumours (Fig. 2) . If this hypothesis was correct, we predicted that the pro-survival effect of vistusertib would be selective for effector T-cells. To investigate this, na€ ıve T-cells were cultured for 3d, in the presence or absence of the prosurvival cytokine IL-7. 38 Under these unstimulated culture conditions, vistusertib did not detectably impact T-cell survival within the dose range investigated (Fig. 6A) . We made a second prediction, that vistusertib treatment could enhance the accumulation of activated/effector phenotype T-cells in vitro. Indeed, we observed that vistusertib potentiated the expression of the effector/memory marker CD44, and greatly increased the presence of cells expressing the CD69 activation marker (Fig. 6B) . Finally, we asked whether vistusertib could enhance survival in conditions that model rate-limiting pro-survival factors in vivo. The autocrine/paracrine production of IL-2 can be limiting for T-cell survival in tumours. 39, 40 In vitro, T-cell activation for 3d in the presence of an aIL-2 neutralizing antibody reduced the frequency of surviving vehicle treated effector cells from »45% to »15% (Fig. 6C, dotted lines) . In contrast, IL-2 neutralization only modestly decreased survival of vistusertib treated effector cells, suggesting that mTOR kinase inhibition can dissociate effector T-cells from a strict requirement for cytokine-mediated survival (Fig. 6C) . Together, these data provide novel insight as to how vistusertib can synergize with immune-checkpoint therapy, suggesting that mTOR inhibitors function to potentiate multiple arms of an anti-tumour immune response to favour accumulation of effector, Th1-polarized, cytotoxic T-cell responses. 
Discussion
mTOR inhibition is classically understood to confer a state of immunosuppression, however a growing body of literature points to context-dependent immune potentiating phenotypes following mTOR inhibition/ablation. We have uncovered an additive effect of combining the clinical mTOR inhibitor vistusertib with immune-checkpoint therapy in cancer. Whilst not efficacious as a monotherapy in the CT-26 model, the combination of vistusertib and aCTLA-4 checkpoint blockade enhanced the accumulation of effector CD8
C T-cells within tumours, driving anti-tumour immune responses. In the MC-38 model, vistusertib enhanced anti-tumour responses conferred by both aCTLA-4 and aPD-L1 administration. These results contribute to a growing body of evidence that suggest mTOR inhibition can promote favourable immune effects. For instance, mTOR inhibitors have been shown to synergize with tumour vaccines, 41, 42 in addition to aPD-L1 immune checkpoint blockade, 12 suggesting that combination of mTOR inhibitors and immune potentiating therapies could represent a broadly applicable therapeutic approach.
How do mTOR inhibitors promote anti-tumour immunity? We have revealed two novel effects of the mTOR inhibitor vistusertib on key immune populations. Firstly in activated DCs, vistusertib modulated cytokine production in a dose-dependent manner, reducing the production of the immune inhibitory cytokine IL-10 whilst enhancing IL-12 (Fig. 4) . This finding is in agreement with several reports showing that mTORC1 inhibition or mTOR ablation can enhance proinflammatory phenotypes in DCs. 25, 26, 29 Vistusertib has previously been shown to limit IL-10 production by tumour cells themselves in diffuse large B-cell lymphoma (DLBCL) cell lines, 43 suggesting this mechanism may extend beyond immune cells to more broadly impact the tumour microenvironment in some contexts. The IL-10:IL-12 axis has been recently identified as an important indicator of chemotherapeutic responses, with IL-10 shown to limit subsequent intratumoral cytotoxic T-cell activity. 44 Moreover, a lower IL-12:IL-10 ratio is a negative prognostic marker, indicative of a suboptimal immune response in HPV-associated pre-neoplastic lesions. 45 In addition, IL-12 is a key Th1 promoting cytokine, which may underlie the enhanced IFNg production observed in vistusertib/aCTLA-4 treated tumours. (Fig. 3) 
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A second novel phenotype was identified when we investigated the dose-dependent effects of vistusertib on weakly activated effector CD8
C T-cells. Whilst high doses of vistusertib could completely inhibit T-cell activation, intermediate doses (<1mM) selectively promoted effector T-cell survival, which was associated with an accumulation of CD25 hi Bcl2 hi cells in culture. Bcl-2 downregulation normally occurs prior to the contraction phase of effector T-cell responses, 47 and this prosurvival benefit of vistusertib appeared to translate in vivo where we observed accumulation of CD8 C T-effector cells within tumours. To our knowledge, this data represents the first evidence of a dose-dependent immune potentiating impact of mTOR signalling in primary effector T-cells. These findings are in keeping with evidence that rapamycin promotes the accumulation of T-cell memory cells during viral infection or vaccination, 36, 48 and that mTOR plays a generalized role to limit biological lifespan. 49 In addition, given that mTOR inhibition is known to promote autophagy, 50 our results may extend findings by Xu et al., who linked autophagy to enhanced effector T-cell survival and differentiation during immune responses to chronic viral infection, 51 Further study will be required to delineate the contributions of downstream mTOR-dependent processes that limit intratumoral immunity.
Altogether, the insights from this study provide a comprehensive, systems-level analysis of the direct tumour-relevant targets of mTOR kinase inhibition. Whilst these studies build on previous pre-clinical observations of combinatorial benefit between the mTORC1 inhibitor rapamycin and a-PD-L1 immune checkpoint blockade in a syngeneic oral cavity cancer model, 12 our results provide novel insight to the mechanisms underlying such potential synergy and extend these findings to a clinical mTOR kinase inhibitor for the first time. Whilst we observed that aCTLA-4 immune-checkpoint blockade was efficient at recruiting/expanding CD8 C T-effector populations in tumours, these cells retained a somewhat exhausted phenotype (Fig. 3) . 22 In contrast, through pleiotropic effects to modulate Th1 promoting innate immune cytokines, and selectively enhance effector CD8
C T-cell viability, vistusertib was able to confer a less suppressive tumour microenvironment (Fig. 3) . These data support a model where careful scheduling/dosing of mTOR inhibitors can directly benefit anti-tumour immunecheckpoint therapy, 52, 53 and provide a clear rationale for exploration of vistusertib/immune checkpoint blockade in the clinic. It is of note that vistusertib treatment resulted in a bell-shaped phenotypic response in T-cells, with the maximal potentiating effect observed at around the IC 50 for pathway inhibition. Given our measurement of rapamycin potency in primary Tcells suggesting IC 50 for mTOR pathway inhibition may be in the sub-pM range (Fig. S1B) , our data predicts that conventional therapeutic doses of rapalogues may be well above the concentration predicted to confer maximal immunological benefit. 54 Interestingly, early phase clinical trials are underway, aiming to understand the dosing/scheduling of rapalogue/ aPD-1 combinations (NCT02423954, and NCT02890069, clinicaltrials.gov), with a view to understand potential combinatorial benefit. However, caution must be taken when extending the conclusions of such studies beyond rapalogue treatment, as clinically important differentiation from mTOR kinase inhibitors may be expected. Nevertheless, our data predicts that combinatorial benefit of mTOR inhibitors may extend to additional immune-checkpoint blocking antibodies or other immunepotentiating therapies beyond PD-1. Moreover, we identify biomarkers (IL-10:IL-12 ratio, non-exhausted effector T-cell accumulation, IFNg production) that may be directly relevant to assess clinical outcomes of mTORi/immune checkpoint combinations.
Materials and methods
Media, reagents and inhibitors
Hanks Balanced Salt Solution (HBSS) was supplemented with 2% FCS and 5mM HEPES (Gibco), complete RPMI (cRPMI) refers to RPMI supplemented with 10% FCS, non-essential amino acids (Thermo Fisher Scientific, 1X concentration), Sodium pyruvate (1 mM), glutamine (4 mM), penicillin and streptomycin (Sigma Aldrich, 1X), 2-mercaptoethanol (50 mM) and HEPES (2 mM). Cell purification buffer consisted of PBS containing 2% FCS and 2mM EDTA.
Rapamycin was purchased from Selleck chemicals, and all other inhibitors were synthesized in-house and stored in DMSO under anoxic conditions (Sigma). LPS-EB was purchased from invivogen and resuspended in dH2O. Recombinant murine IL-2 and IL-7 were purchased from peprotech. a-mouse IL-2 neutralizing antibody (clone JES6-1A12) was purchased from eBioscience.
Mice
Male or female BALB/c, C57BL-6 and nude mice were purchased from Envigo and housed under specific pathogen free conditions at the CRUK Cambridge institute animal facility. All procedures were carried out in accordance with UK home office regulations and with approved institutional guidelines.
CT-26 (5x10 6 cells/mouse) or MC-38 (5x10 6 cells/mouse) tumour cells were implanted subcutaneously (s.c.) in the left flank of female mice. Four days (CT-26) or one day (MC-38) after implantation mice were randomised by body weight and dosed dosed at 15 mg/kg daily p.o. with vistusertib in 1% Polysorbate and 20 mg/kg 2 times a week, i.p. with anti-CTLA-4 (9D9) IgG1, or 10 mg/kg 2 times a week with anti-PD-L1 (D265A) IgG1 in PBS. At end of study tumour tissues were then transferred into the gentleMACS C Tube containing RPMI. Tumour samples were processed using the mouse tumour dissociation kit from Miltenyi Biotec. Cells were liberated from tumours for downstream application using a mouse tumour dissociation kit and octodissociator (Miltenyi) according to manufacturer's instructions.
Plasma pharmacokinetic analysis of vistusertib concentrations was performed as previously described. 6 
Flow cytometry
The following fluorophore-conjugated antibodies were used in this study: CD5-FITC (53-7. 3), phospho-S6(ser240/ 244)-Alexa647, (Cell signaling technologies cat. #2215), phospho-Akt(ser473)-PE (M89-61), phospho-4Ebp1(Thr36/45)-PE (M31-16), Bcl2-PE (clone BCL/10C4), IFNg-FITC (Clone XMG1.2). All antibodies were purchased from Biolegend, eBioscience, BD or Cell signaling technology. Cells were stained with a viability marker (Live/Dead Aqua Ò , Thermofisher scientific) according to manufacturer's instructions, and stained for surface/intracellular markers as described previously. 28 CellTrace Violet (CTV) labelling was performed in PBS containing 0.05% BSA and 1.6 mM CTV for 10 minutes at 37 C.
CTV was then quenched following two washes with ice cold MACS buffer. Detection of phospho-specific antibodies was performed following a 25' stimulation of T-cells at 37 C. Cells were fixed for 10' at 37 C with BD phosflow fixation buffer I, permeabilized for 30' on ice with pre-chilled (-20 C) BD phosflow perm buffer III, and stained for 40' on ice with BD phosflow perm/wash buffer I, according to manufacturer's instructions. For detection of intracellular IFNg, single cell suspensions were derived from tumours and subsequently restimulated with 100ng/mL PMA, 1 mg/mL Ionomycin, 1X golgi stop (BD) and 1X golgi plug (BD) in cRPMI (3.5h, 37 C, 5% CO 2 ), before fixation/permeabiliation with a cytofix/cytoperm kit (BD) according to manufacturer's instructions.
Samples were filtered through 40 mm cell strainers and acquired on a BD LSRFortessa cytometer. Downstream analysis was performed using FlowJo software (V10) and viSNE (Cytobank) high-dimensional, single-cell analysis. 21 
Immunohistochemistry
Immunohistochemical analysis of paraffin-embedded CT-26 tumours were performed with Phospho-Akt (Ser473) clone 736E11 (Cell Signaling Technology). Cytoplasmic staining was quntified using Aperio Imangescope (Leica Byosystems).
Cytokine quantitation
ELISA quantification of IL-10, IL-12p40, IL-12p70, IL-6 and TNF was performed using BD OptEIA ELISA kits according to manufacturer's instructions. Meso Scale Discovery (MSD) analysis was performed using an MSD V-PLEX Mouse Cytokine 19-Plex kit according to manufacturer's instructions. IFNg was quantified in tumour aqueous extract using a LEGENDplex TM kit (Biolegend).
Cell culture
Bone marrow DCs (BMDCs) were generated and cultured as described previously. 28 Na€ ıve CD8 T-cells were purified from splenocytes using an EasySep TM Mouse Na€ ıve CD8C T Cell Isolation Kit (Stemcell Technologies) and cell purification buffer, according to manufacturer's instructions. T-cells were cultured in cRPMI at 2.5-5x10 5 cells/mL in a 96-well plate. Cells were activated with 1 mg/mL plate bound aCD3e (145.2C11) and 1 mg/mL soluble aCD28 (37.51), or with Dynabeads Ò mouse T-cell activator beads (1:1 bead:cell ratio) at 37 C in a humidified incubator (5% CO 2 ).
Gene profiling and analysis
Total RNA was isolated from snap frozen tissue and cells using Qiashredder and Qiazol Lysis Buffer on Qiacube-HT following the RNeasy 96 QIAcube HT total RNA cell with DNase protocol according to manufacturer's instructions (Qiagen). Reverse transcription was performed from 50ng of total RNA (Thermo Scientific #4374967) and further pre-amplified (Thermo Scientific #4488593; 14 cycles) using a pool of TaqMan primers (listed in 
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